Vice president and general manager of the coronary and peripheral vascular business at Medtronic.

‘.. Sean Salmon, vice president and general manager of the coronary and peripheral vascular business at Medtronic, to the head – to-head study, the findings together: ‘the results of the ENDEAVOR IV show that for every 1,000 patients treated with either Endeavor or Taxus, similar numbers would need to repeat an operation for two years, but compared to the Taxus patients would Endeavor patients experiencing eight fewer heart attacks between one year and two years after implantation While these calculations a population of patients as they take over in ENDEAVOR. 25 April 2008.data the body of knowledge, with the major therapy major therapy – selection decisions armed for their patients.

About MedtronicMedtronic , headquartered in Minneapolis, is the global leader in medical technology, alleviating pain, restoring health, and extending life for millions of people around the world.All forward-looking statements subject to risks and uncertainties such as those described Medtronic ‘s Annual Report on Form 10-K for the year ended 25 April 2008. Actual results may differ materially from the anticipated results.By Dr. Light to Breast Cancer Detection Shedtop research of Northumbrian and Newcastle Universities of pioneers to safer and to a safer and effective way of detection of breast cancer. David Smith of Northumbrian School of Computing, Engineering and Information Sciences, developing a microwave – based technology, the hologram quality images of hidden objects be such as you generating tumor.